Australien - engelska - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - esomeprazole magnesium, quantity: 41.4 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: povidone; macrogol 400; macrogol 6000; microcrystalline cellulose; diethyl phthalate; hypromellose phthalate; crospovidone; macrogol 4000; sodium stearylfumarate; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; maize starch; sucrose - gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazolesolution administered by intravenous infusion,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole magnesium, quantity: 20.6 mg - tablet, enteric coated - excipient ingredients: copovidone; simethicone; purified talc; glyceryl monostearate; stearic acid; polysorbate 80; titanium dioxide; colloidal anhydrous silica; propylene glycol; macrogol 6000; hypromellose; microcrystalline cellulose; magnesium stearate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; crospovidone; iron oxide red; sucrose; hydrolysed maize starch; maize starch - gastro-oesophageal reflux disease (gord). ,symptomatic gord. ,the relief of heartburn and other symptoms associated with gord.,erosive oesophagitis. ,the treatment and prevention of relapse.,peptic ulcers. ,the treatment of duodenal and gastric ulcer.,combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection.,the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs.,the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer.,long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be helicobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective.,zollinger-ellison syndrome. ,the treatment of zollinger-ellison syndrome.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole magnesium, quantity: 20.6 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; propylene glycol; simethicone; stearic acid; macrogol 6000; crospovidone; titanium dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; microcrystalline cellulose; copovidone; polysorbate 80; hypromellose; purified talc; povidone; iron oxide red; maize starch; sucrose; hydrolysed maize starch - gastro-oesophageal reflux disease (gord). ,symptomatic gord. ,the relief of heartburn and other symptoms associated with gord.,erosive oesophagitis. ,the treatment and prevention of relapse.,peptic ulcers. ,the treatment of duodenal and gastric ulcer.,combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection.,the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs.,the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer.,long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be helicobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective.,zollinger-ellison syndrome. ,the treatment of zollinger-ellison syndrome.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: glyceryl monostearate; povidone; purified water; crospovidone; polysorbate 80; silicon dioxide; hypromellose phthalate; microcrystalline cellulose; pregelatinised maize starch; hyprolose; iron oxide red; purified talc; methacrylic acid - ethyl acrylate copolymer (1:1); macrogol 6000; light magnesium oxide; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypers

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: crospovidone; purified talc; light magnesium oxide; purified water; pregelatinised maize starch; microcrystalline cellulose; silicon dioxide; glyceryl monostearate; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; iron oxide red; macrogol 6000; hyprolose; hypromellose phthalate; macrogol 400; maize starch; sucrose; titanium dioxide; hypromellose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypers

Australien - engelska - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified water; purified talc; crospovidone; light magnesium oxide; hyprolose; macrogol 6000; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; silicon dioxide; iron oxide red; pregelatinised maize starch; povidone; microcrystalline cellulose; hypromellose phthalate; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australien - engelska - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium trihydrate, quantity: 44.528 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: polysorbate 80; hypromellose phthalate; pregelatinised maize starch; macrogol 6000; light magnesium oxide; purified water; povidone; glyceryl monostearate; silicon dioxide; microcrystalline cellulose; crospovidone; purified talc; iron oxide red; methacrylic acid - ethyl acrylate copolymer (1:1); hyprolose; macrogol 400; titanium dioxide; hypromellose; maize starch; sucrose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australien - engelska - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium trihydrate, quantity: 44.528 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); crospovidone; purified water; hypromellose phthalate; purified talc; polysorbate 80; macrogol 6000; povidone; microcrystalline cellulose; iron oxide red; silicon dioxide; pregelatinised maize starch; glyceryl monostearate; light magnesium oxide; hyprolose; macrogol 400; titanium dioxide; hypromellose; maize starch; sucrose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australien - engelska - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified talc; iron oxide red; polysorbate 80; glyceryl monostearate; silicon dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); light magnesium oxide; hyprolose; microcrystalline cellulose; hypromellose phthalate; povidone; purified water; crospovidone; macrogol 6000; pregelatinised maize starch; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australien - engelska - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium -